MedTrace Logo

Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients

NCT00304772 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2024-06-14

No results posted yet for this study

Summary

The purpose of this study is to verify the equivalence in clinical efficacy of fluconazole and micafungin for the treatment of Candida bloodstream infection in non-neutropenic patients.

Conditions

Interventions

DRUG

Fluconazole

400mg/day

DRUG

Micafungin

150mg/day

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Kyoto University

    lead OTHER

Principal Investigators

  • Satoshi Ichiyama, MD, PhD · Professor of Medicine, Department of Clinical Laboratory Medicine, Kyoto University Hospital

  • Shunji Takakura, MD, PhD · Instructor in Medicine, Department of Clinical Laboratory Medicine, Kyoto University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304772 on ClinicalTrials.gov